4.5 Review

Strategies for the discovery of therapeutic aptamers

期刊

EXPERT OPINION ON DRUG DISCOVERY
卷 6, 期 1, 页码 75-87

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/17460441.2011.537321

关键词

aptamers; in vitro selection; oligonucleotide; phosphorodithioate; SELEX; thioaptamer

资金

  1. Department of Defense [W81XWH-09-10212]
  2. National Institute of Health [R01CA128797, AI 27744, GM 084552, RC2GM092599ARRA, N01-HV-28184, HHSN 272200800048C]
  3. Welch Foundation [H-1296]
  4. DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER
  5. NATIONAL CANCER INSTITUTE [R01CA128797] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027744] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM084552, R44GM084552, RC2GM092599] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Importance of the field: Therapeutic aptamers are synthetic, structured oligonucleotides that bind to a very broad range of targets with high affinity and specificity. They are an emerging class of targeting ligand that show great promise for treating a number of diseases. A series of aptamers currently in various stages of clinical development highlights the potential of aptamers for therapeutic applications. Areas covered in this review: This review covers in vitro selection of oligonucleotide ligands, called aptamers, from a combinatorial library using the Systematic Evolution of Ligands by Exponential Enrichment process as well as the other known strategies for finding aptamers against various targets. What the reader will gain: Readers will gain an understanding of the highly useful strategies for successful aptamer discovery. They may also be able to combine two or more of the presented strategies for their aptamer discovery projects. Take home message: Although many processes are available for discovering aptamers, it is not easy to discover an aptamer candidate that is ready to move toward pharmaceutical drug development. It is also apparent that there have been relatively few therapeutic advances and clinical trials undertaken due to the small number of companies that participate in aptamer development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据